Panacea Biotec Limited, an Indian biotechnology firm, specializes in the full spectrum of activities for pharmaceutical formulations and vaccines, including research, development, manufacturing, and marketing. The company operates through two primary divisions: Vaccines and Formulations. Its comprehensive range of prescription products addresses numerous therapeutic areas such as pain management, diabetes and cardiovascular conditions, oncology, renal disease, osteoporosis, and gastro-intestinal health. On the vaccine front, Panacea Biotec develops and produces key immunizations, including those for pneumococcal disease, dengue (tetravalent), typhoid (conjugate), and universal influenza. Beyond its domestic operations in India, the company extends its market reach globally, exporting products to approximately 36 countries. This international presence includes the United States, Germany, the Russian Federation, Turkey, Bosnia, Tanzania, Kenya, Serbia, Vietnam, the Philippines, and Sri Lanka, among others. Panacea Biotec is also involved in significant collaborations, notably with the Russian Direct Investment Fund for the manufacturing of the Sputnik-V COVID-19 vaccine. Furthermore, it partners with the Coalition for Epidemic Preparedness Innovations and the Translational Health Science and Technology Institute to advance vaccine candidates targeting SARS-CoV-2 variants and other Beta coronaviruses. Established in 1984, Panacea Biotec Limited is headquartered in New Delhi, India.
